IL-1R antagonists such as anakinra, already tried for ECD treatment [183,184], rilonacept, and canakinumab, with taking care of serious unwanted side-effects, might interrupt the out-of-control IL-1 loop, providing a therapeutic strategy for LCH treatment. This evidence concerns the gene IL1A and Langerhans cell histiocytosis.